AZ colon cancer drug is a bust in PhIII

AstraZeneca (NYSE: AZN) has been handed another setback in its quest to come up with some major new products quickly. Researchers say that their latest Phase III clinical trial of Recentin as a first-line therapy for colon cancer was a bust, with the therapy proving no more effective than the chemo drugs currently available for improving the overall survival rate of patients. The drug did meet the co-primary endpoint of progression-free survival, but that wasn't enough to convince the company...